13.21  -0.79 (-5.64%)		07-13 16:00
Open: 13.935 High: 13.95 Volume: 1,224,072		Pre. Close: 14 Low: 13.035 Market Cap: 901(M)

Short term
Mid term
Targets	6-month :	16.83	1-year :	19.66
Resists	First :	14.41	Second :	16.83
Pivot price	13.12
Supports	First :	11.91	Second :	10.36
MAs	MA(5) :	13.6	MA(20) :	12.66
	MA(100) :	9.52	MA(250) :	5.44
MACD	MACD :	0.6	Signal :	0.6
%K %D	K(14,3) :	76.5	D(3) :	79
RSI	RSI(14): 58
52-week	High :	14.41	Low :	1.35

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CLYM ] has closed below upper band by 45.6%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	13.96 - 14.03	14.03 - 14.08
Low:	12.87 - 12.96	12.96 - 13.02
Close:	13.08 - 13.22	13.22 - 13.3

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Thu, 09 Jul 2026
Climb Bio Inc. (CLYM) Edges Lower Amid Mixed Biotech Sentiment, Key Support Levels in Focus - Weak Sell Signals - DonanımHaber

Mon, 29 Jun 2026
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index - marketscreener.com

Mon, 29 Jun 2026
Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark - marketscreener.com

Fri, 26 Jun 2026
Price to earnings forward of Climb Bio, Inc. – NASDAQ:CLYM - TradingView

Thu, 14 May 2026
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - GlobeNewswire

Thu, 07 May 2026
$110M financing gives Climb Bio room for multiple 2026 drug data readouts - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	57 (M)
Shares Float	41 (M)
Held by Insiders	0.3 (%)
Held by Institutions	64.5 (%)
Shares Short	5,100 (K)
Shares Short P.Month	1,910 (K)

EPS	-0.77
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.09
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-21.3 %
Return on Equity (ttm)	-31 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-53 (M)
Levered Free Cash Flow	-35 (M)

PE Ratio	-17.16
PEG Ratio	0
Price to Book value	4.26
Price to Sales	0
Price to Cash Flow	-14.2

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.